This site is intended for U.S. healthcare professionals.
NCCN Guidelines® recommend crizotinib (XALKORI) as a preferred first‑line treatment option for ROS1‑positive metastatic NSCLC and as a first‑line treatment option for ALK‑positive metastatic NSCLC (Category 1)1*†
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.